Stapled Peptides Block Alzheimer's Amyloid Clumping and Break Up Existing Clumps
Stapled peptides modulated amyloid-beta aggregation and disrupted preformed fibrils while showing improved proteolytic stability — a dual-action approach to Alzheimer's disease.
Quick Facts
What This Study Found
The team used a "tail-to-side chain" stapling method to create a library of modified peptides. These stapled peptides modulated the self-association and fibril formation of amyloid-beta 1-40, the protein fragment central to Alzheimer's pathology.
The stapled peptides also disrupted preformed fibrillar aggregates, converting them into non-toxic species. This dual action, preventing new aggregation and breaking up existing fibrils, is particularly valuable.
The ring shape made the peptides significantly more resistant to proteolytic enzymes, which would normally break down linear peptides quickly. This improved stability is essential for any potential therapeutic use.
Key Numbers
Library of stapled peptides; modulated Aβ1-40 aggregation; disrupted preformed fibrils; increased proteolytic stability
How They Did This
This was a laboratory study. Researchers synthesized stapled peptides through lactamization (forming a ring via a chemical bond). They tested the peptides against amyloid-beta 1-40 aggregation using standard fibrillogenesis assays and evaluated proteolytic stability in the presence of enzymes.
Why This Research Matters
Alzheimer's disease has no effective treatment targeting amyloid aggregation. Finding peptides that can both prevent new clumps and break up existing ones addresses two aspects of the disease at once.
The improved enzyme resistance from stapling solves a major problem with peptide drugs, which usually get broken down too quickly to be useful.
The Bigger Picture
Alzheimer's disease has no effective amyloid-targeting treatment despite decades of effort. Peptides that can both prevent new aggregation and dissolve existing deposits address the disease at two stages, potentially offering more benefit than agents targeting only one.
What This Study Doesn't Tell Us
This was entirely a lab study with no cell viability, animal, or human testing. Whether these peptides can cross the blood-brain barrier and work in a living brain is unknown.
The non-toxic nature of the disrupted aggregates was stated but the extent of toxicity testing was limited.
Questions This Raises
- ?Can these stapled peptides cross the blood-brain barrier?
- ?How do they compare to anti-amyloid antibodies like lecanemab?
- ?Would they be effective at the stage of disease where amyloid is already widespread?
Trust & Context
- Key Stat:
- Dual action prevents new amyloid-beta aggregation AND disrupts preformed fibrils — addressing both disease prevention and existing pathology
- Evidence Grade:
- Preliminary evidence from in vitro studies. No cell viability, blood-brain barrier penetration, or animal data.
- Study Age:
- Published in 2020. The Alzheimer's treatment landscape has evolved with approval of anti-amyloid antibodies since this study.
- Original Title:
- Peptidomimetics prepared by tail-to-side chain one component peptide stapling inhibit Alzheimer's amyloid-β fibrillogenesis.
- Published In:
- Chemical science, 11(16), 4171-4179 (2020)
- Database ID:
- RPEP-04892
Evidence Hierarchy
Frequently Asked Questions
What is amyloid-beta and why target it in Alzheimer's?
Amyloid-beta is a protein fragment that clumps together in the brains of Alzheimer's patients. These clumps are believed to damage brain cells. Drugs that prevent clumping or dissolve existing clumps might slow the disease.
How are stapled peptides different from anti-amyloid antibodies?
Stapled peptides are small, stable molecules that could potentially be manufactured more cheaply and might cross the blood-brain barrier more easily than large antibodies, though this has not yet been demonstrated.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04892APA
Kalita, Sujan; Kalita, Sourav; Paul, Ashim; Sarkar, Amar; Mandal, Bhubaneswar. (2020). Peptidomimetics prepared by tail-to-side chain one component peptide stapling inhibit Alzheimer's amyloid-β fibrillogenesis.. Chemical science, 11(16), 4171-4179. https://doi.org/10.1039/c9sc06076f
MLA
Kalita, Sujan, et al. "Peptidomimetics prepared by tail-to-side chain one component peptide stapling inhibit Alzheimer's amyloid-β fibrillogenesis.." Chemical science, 2020. https://doi.org/10.1039/c9sc06076f
RethinkPeptides
RethinkPeptides Research Database. "Peptidomimetics prepared by tail-to-side chain one component..." RPEP-04892. Retrieved from https://rethinkpeptides.com/research/kalita-2020-peptidomimetics-prepared-by-tailtoside
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.